Collegium Pharmaceutical, Inc. COLL Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| Belbuca | $222.64M+4.9% | $221.65M+4.9% | $217.72M+6.0% | $212.67M+7.6% | $212.26M+12.6% | |
| Jornay PM | $159.21M— | $148.86M— | $132.25M— | $98.4M— | —— | |
| Nucynta ER | $79.53M+4.3% | $80.99M+6.9% | $79.98M+2.6% | $76.94M-4.8% | $76.27M-5.5% | |
| Nucynta IR | $113.97M+11.5% | $115.31M+14.5% | $110.12M+6.2% | $103.5M+0.2% | $102.2M-3.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Collegium Pharmaceutical, Inc. break its business down?
- Collegium Pharmaceutical, Inc. (COLL) reports product revenues, net by product across 9 parts — Belbuca, Jornay PM, Nucynta ER AG, Nucynta ER and Nucynta IR AG. Each is extracted from the segment footnotes and tracked over time.
- Where does Collegium Pharmaceutical, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Collegium Pharmaceutical, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
